Variant libraries of the immunological synapse and synthesis thereof

Patent metadata

Field	Value
Publication number	US-10907274-B2
Application number	US-201715844395-A
Country	US
Kind code	B2
Filing date	Dec 15, 2017
Priority date	Dec 16, 2016
Publication date	Feb 2, 2021
Grant date	Feb 2, 2021

Abstract

Disclosed herein are methods for the generation of highly accurate nucleic acid libraries encoding for predetermined variants of a nucleic acid sequence. The nucleic acid sequence may encode for all or part of a TCR or a TCR-binding antigen. The degree of variation may be complete, resulting in a saturated variant library, or less than complete, resulting in a non-saturating library of variants. The variant nucleic acid libraries described herein may designed for further processing by transcription or translation. The variant nucleic acid libraries described herein may be designed to generate variant RNA, DNA and/or protein populations. Further provided herein are method for identifying variant species with increased or decreased activities, with applications in regulating biological functions and the design of therapeutics for treatment or reduction of a disease, such as cancer.

First claim

What is claimed is:

1. A method of synthesizing a nucleic acid library, comprising:
a. providing a first set of preselected polynucleotide sequences encoding for at least 3000 variant sequences of a TCR gene or gene fragment, wherein each variant sequence comprises at least one variation at a preselected codon for an amino acid residue in an antigen contacting interface;
b. synthesizing the first set of preselected polynucleotide sequences;
c. screening binding activity for proteins encoded by the first set of polynucleotide sequences;
d. providing a second set of preselected polynucleotide sequences encoding for at least one variant sequence of the TCR gene or gene fragment, where each variant sequence comprises at least one variation at a preselected codon for an amino acid residue in the TCR gene or gene fragment in a region encoding a constant domain;
e. synthesizing the second set of preselected polynucleotide sequences; and
f. screening a second activity for proteins encoded by the second set of polynucleotide sequences.

2. The method of claim 1 , wherein the at least one variation in the first set of preselected polynucleotide sequences is in a variable or a constant domain coding region of the TCR gene or gene fragment.

3. The method of claim 2 , wherein the variable domain is a variable domain of TCR alpha, TCR beta, TCR gamma, or TCR delta, and wherein the constant domain is a constant domain of TCR alpha, TCR beta, TCR gamma, or TCR delta.

4. The method of claim 1 , wherein the antigen is a cancer antigen.

5. The method of claim 1 , wherein each variant sequence in the first set of preselected polynucleotide sequences comprises up to 100 variations at preselected codons for amino acid residues in the antigen contacting interface.

6. The method of claim 1 , wherein the second activity is cancer cell killing, protein expression, or protein stability.

7. The method of claim 1 , wherein each variant sequence in the second set of preselected polynucleotide sequences comprises up to 100 variations at preselected codons for amino acid residues in the TCR gene or gene fragment in a region encoding a constant domain.

Assignees

• Twist Bioscience Corp

Inventors

• Cox Anthony
• Chen Siyuan

Classifications

• G01N33/575

  for cancer · CPC title

• A61K40/4269

  NY-ESO · CPC title

• A61K40/4268

  MAGE · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• A61K40/32

  T-cell receptors [TCR] · CPC title